Response time for ecallantide (cas 460738-38-9) treatment of acute hereditary angioedema attacks
-
Add time:07/15/2019 Source:sciencedirect.com
BackgroundHereditary angioedema (HAE) is a rare, debilitating, and potentially fatal disease characterized by acute attacks of swelling that can affect the abdomen/gastrointestinal tract, larynx, face, genitals, and extremities. ecallantide (cas 460738-38-9) is a novel plasma kallikrein inhibitor developed for the treatment of acute HAE attacks.
We also recommend Trading Suppliers and Manufacturers of ecallantide (cas 460738-38-9). Pls Click Website Link as below: cas 460738-38-9 suppliers
Prev:Effectiveness of ecallantide (cas 460738-38-9) in treating angiotensin-converting enzyme inhibitor–induced angioedema in the emergency department
Next:Outcomes after ecallantide (cas 460738-38-9) treatment of laryngeal hereditary angioedema attacks) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide (cas 460738-38-9), a novel kallikrein inhibitor07/18/2019
- ecallantide (cas 460738-38-9) (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies07/17/2019
- Outcomes after ecallantide (cas 460738-38-9) treatment of laryngeal hereditary angioedema attacks07/16/2019
- Effectiveness of ecallantide (cas 460738-38-9) in treating angiotensin-converting enzyme inhibitor–induced angioedema in the emergency department07/14/2019
- ecallantide (cas 460738-38-9) for the Acute Treatment of Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema: A Multicenter, Randomized, Controlled Trial07/13/2019
- Analysis of hereditary angioedema attacks requiring a second dose of ecallantide (cas 460738-38-9)07/12/2019
- Characterization of Anaphylaxis After ecallantide (cas 460738-38-9) Treatment of Hereditary Angioedema Attacks07/11/2019
